Influvac
| Influenza (Flu) |
|---|
 |
| Types |
| Vaccines |
| Treatment |
| Pandemics |
| Outbreaks |
| See also |
Influvac is a sub-unit vaccine produced and marketed by Abbott Laboratories. It contains inactivated purified surface fragments (sub-units) from the three different strains of the influenza virus (A/H1N1, A/H3N2, and Influenza B Virus) that are selected and distributed by the World Health Organization, on the basis of their latest recommendations.[1]
In February 2010, Abbott acquired the vaccines sub-unit from Solvay Pharmaceuticals included in its $6.2 billion purchase[2] and the sub-unit influenza vaccine - Influvac has been commercially available on the market since the early nineteen-eighties.[1] With the acquisition of Solvay, Abbott retained access to the Eastern European, Middle Eastern & Latin American markets. Approximately $850 million of sales revenue from vaccines was reported by Solvay Pharmaceuticals in 2009.[2]
References
- 1 2 Giezeman, K.M.; J. Nauta; I.A. de Bruijn; A.M. Palache (2009). "Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity". Vaccine. Elsevier. 27: 2414. doi:10.1016/j.vaccine.2009.02.008.
- 1 2 "Abbott Halts Influvac Sale". Drug Discovery & Development.